(Q37272164)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Srdan Verstovsek

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Eshetu G. Atenafu

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Parameswaran Hari

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

Uday Popat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

23

Richard Champlin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

8

Roni Tamari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

15

Navneet S Majhail

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

11

Usama Gergis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

13

Rammurti T Kamble

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

7

John Mascarenhas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Laura C Michaelis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Veena Fauble

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Donal McLornan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Rebecca Klisovic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Murat O Arcasoy

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

James Davies

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Oluchi C Ukaegbu

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

John M Storring

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Rizwan Romee

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antonio Pagliuca

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sumithira Vasu

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Brenda Ernst

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ahmad Hanif

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Vikas Gupta

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

1 reference

19 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

Biology of Blood and Marrow Transplantation

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

432-440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

28 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Allogeneic stem cell transplantation for myelofibrosis in 2012.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Defining the intensity of conditioning regimens: working definitions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Outcome of transplantation for myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

A gain-of-function mutation of JAK2 in myeloproliferative disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Ruxolitinib withdrawal syndrome leading to tumor lysis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030817

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

3 September 2018

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

1 reference

12 December 2020

Long-term outcome of treatment with ruxolitinib in myelofibrosis

1 reference

12 December 2020

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

1 reference

12 December 2020

1 reference

12 December 2020

10.1016/J.BBMT.2015.10.005

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493563%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

26493563

1 reference